Consistently, PAX5 alterations (rearrangements, deletions, and sequence variants) that lead to the suppression or loss of its physiological function are involved in BCP‐ALL development in approximately 30% of patients [4]. Here, PAX5 is linked to acute lymphoblastic leukemia.